Tristan Briones, MD
Physical Medicine & Rehabilitation · Owensboro, KYNPI 1386673010
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Nevro Corp. at 34.4% of the total. Reporting peaked in 2019 at $556 and has fallen 56.8% since, to $241 in 2025.
Across 123 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$843
- AbbVie$253
- Collegium Pharmaceutical, Inc.$226
- Medtronic$145
- Globus Medical$142
- Almatica Pharma LLC$115
- plus $731 from 20 others
What the payments were for
- Food & beverage$2,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 33 | $843 |
| AbbVie(2 entities) | 14 | $253 |
| Collegium Pharmaceutical, Inc. | 13 | $226 |
| Medtronic | 4 | $145 |
| Globus Medical | 7 | $142 |
| Almatica Pharma LLC | 6 | $115 |
| Pfizer | 6 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Si-bone, Inc. | 4 | $69 |
| Abbott | 3 | $58 |
| Boston Scientific | 4 | $56 |
| Lilly USA, LLC | 3 | $56 |
| Daiichi Sankyo Inc. | 4 | $56 |
| Redhill Biopharma Inc. | 2 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Saol Therapeutics Inc. | 2 | $32 |
| Vertex | 1 | $23 |
| Novartis | 1 | $19 |
| Bioventus LLC | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Shionogi Inc | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Flowonix Medical Incorporated | 1 | $13 |
| Metacel Pharmaceuticals LLC | 1 | $13 |
| Acacia Pharma Inc | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,455 in reported general payments places this provider in the 85th percentile of 104 physical medicine & rehabilitation providers in Kentucky.
See all physical medicine & rehabilitation providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 37 | $67,942 |
| RelistorMethylnaltrexone Bromide | 12 | $32,766 |
| GraliseGabapentin | 26 | $25,814 |
| Buprenorphine | 79 | $24,081 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 959 | $20,059 |
| ButransBuprenorphine | 32 | $15,670 |
| BelbucaBuprenorphine Hcl | 21 | $12,487 |
| OxycontinOxycodone Hcl | 13 | $10,135 |
| Gabapentin | 754 | $6,590 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 272 | $5,932 |
| MovantikNaloxegol Oxalate | 12 | $5,637 |
| Pregabalin | 141 | $4,976 |
| SymproicNaldemedine Tosylate | 11 | $4,780 |
| Baclofen | 169 | $1,891 |
| Diclofenac Sodium | 60 | $1,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $253 | $67,94237 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $83 | $32,76612 claims |
| Almatica Pharma LLCGralise | $115 | $25,81426 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $226 | $12,48721 claims |
| Redhill Biopharma Inc.Movantik | $43 | $5,63712 claims |
| Shionogi IncSymproic | $14 | $4,78011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 104 physical medicine & rehabilitation providers in Kentucky.
Other physical medicine & rehabilitation in Owensboro
- Joseph PorterOwensboro$4K
- Trasey FalconeOwensboro$296
- Clay GuynnLexington$193K
- Lester DuplechanCrestview Hills$28K
- Darryl KaelinLouisville$19K
- Dhruv PandyaAshland$14K
- Raechel PercyLexington$8K
- Ushma PatelAshland$7K
- Melanie LedfordLexington$6K
- Cecil HollenLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.